KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Rigel Pharmaceuticals (RIGL) Leases (2019 - 2025)

Rigel Pharmaceuticals has reported Leases over the past 7 years, most recently at $920000.0 for Q4 2025.

  • For Q4 2025, Leases rose 273.98% year-over-year to $920000.0; the TTM value through Dec 2025 reached $920000.0, up 273.98%, while the annual FY2025 figure was $920000.0, 273.98% up from the prior year.
  • Leases for Q4 2025 was $920000.0 at Rigel Pharmaceuticals, down from $1.0 million in the prior quarter.
  • Over five years, Leases peaked at $15.9 million in Q1 2021 and troughed at $246000.0 in Q4 2024.
  • A 5-year average of $4.0 million and a median of $1.2 million in 2023 define the central range for Leases.
  • Biggest five-year swings in Leases: tumbled 85.03% in 2023 and later skyrocketed 273.98% in 2025.
  • Year by year, Leases stood at $9.7 million in 2021, then crashed by 80.11% to $1.9 million in 2022, then tumbled by 55.39% to $861000.0 in 2023, then crashed by 71.43% to $246000.0 in 2024, then skyrocketed by 273.98% to $920000.0 in 2025.
  • Business Quant data shows Leases for RIGL at $920000.0 in Q4 2025, $1.0 million in Q3 2025, and $1.2 million in Q2 2025.